Cinacalcet in hyperfunctioning parathyroid diseases

Therapeutic Apheresis and Dialysis

Volumn 13, Issue SUPPL. 1, 2009, Pages

  Imanishi, Yasuo ^a   Inaba, Masaaki ^a   Kawata, Takehisa ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium sensing receptor (CaR); Chronic kidney disease (CKD); CKD mineral and bone disorder (CKD MBD); Cyclin D1; Hyperparathyroidism; Parathyroid hormone (PTH)

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; N [2 HYDROXY 3 (2 CYANO 3 CHLOROPHENOXY)PROPYL] 1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; TECALCET; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR CALCIUM; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; NONHUMAN; OSTEITIS FIBROSA; PARATHYROID HORMONE RELEASE; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RENAL OSTEODYSTROPHY; REVIEW; UREMIA;

ANIMALS; CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; NAPHTHALENES; PARATHYROID HORMONE; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; UREMIA;

EID: 70349316168     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00768.x     Document Type: Review

References (35)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006 69 (11 1945 1953.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 31 (4 607 617.
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 342 (20 1478 1483.
4. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001 12 (10 2131 2138.
5. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 (15 1516 1525.
6. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005 16 (3 800 807.
7. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005 20 (10 2186 2193.
8. Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008 3 (1 36 45.
9. Imanishi Y, Inaba M, Kawata T, Nishizawa Y. Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 2009 4 (7 727 740.
10. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983 56 (3 572 581.
11. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003 348 (17 1656 1663.
12. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007 117 (12 4003 4008.
13. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007 18 (10 2683 2688.
14. Carling T, Rastad J, Szabo E, Westin G, Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 2000 85 (5 2000 2003.
15. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996 81 (4 1598 1606.
16. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995 95 (5 2047 2053.
17. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998 83 (5 1766 1770.
18. Imanishi Y, Tahara H, Palanisamy N et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 2002 13 (6 1490 1498.
19. 2+-sensing receptor from bovine parathyroid. Nature 1993 366 (6455 575 580.
20. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993 75 (7 1297 1303.
21. Ho C, Conner DA, Pollak MR et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995 11 (4 389 394.
22. Kifor O, MacLeod RJ, Diaz R et al. Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am J Physiol Renal Physiol 2001 280 (2 F291 302.
23. 2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995 80 (11 3107 3110.
24. Imanishi Y, Inaba M, Nishizawa Y, Morii H, Otani S. Involvement of polyamines in the proliferation of bovine parathyroid cells. Miner Electrolyte Metab 1995 21 (1-3 197 200.
25. 3 on bovine parathyroid cells. J Steroid Biochem Mol Biol 1999 70 (4-6 243 248.
26. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004 308 (2 627 635.
27. Kawata T, Imanishi Y, Kobayashi K et al. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 2006 24 (4 300 306.
28. Imanishi Y, Koyama H, Inaba M et al. Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney Int 1996 49 (2 499 505.
29. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005 67 (2 467 476.
30. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998 53 (2 448 453.
31. Kawata T, Nagano N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008 74 (10 1270 1277.
32. Kawata T, Imanishi Y, Kobayashi K et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 2005 153 (4 587 594.
33. Imanishi Y, Hosokawa Y, Yoshimoto K et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001 107 (9 1093 1102.
34. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004 279 (18 18990 18997.
35. Nemeth EF, Delmar EG, Heaton WL et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther 2001 299 (1 323 331.